- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00573469
Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
2. juli 2012 opdateret af: AstraZeneca
A Multicentre, Double-blind, Randomised, Parallel-group, Phase II Study to Assess Efficacy and Safety of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
The purpose of this study is to determine whether treatment with D9421-C for 8 weeks in Japanese patients with mild to moderate active Crohn's disease will improve their symptoms of Crohn's disease and quality of life.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
75
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Fukuoka, Japan
- Research Site
-
Hiroshima, Japan
- Research Site
-
Itami, Japan
- Research Site
-
Kyoto, Japan
- Research Site
-
Nishinomiya, Japan
- Research Site
-
Oita, Japan
- Research Site
-
Osaka, Japan
- Research Site
-
Tokyo, Japan
- Research Site
-
Toyama, Japan
- Research Site
-
-
Aichi
-
Nagoya, Aichi, Japan
- Research Site
-
-
Chiba
-
Sakura, Chiba, Japan
- Research Site
-
-
Fukuoka
-
Chikushino, Fukuoka, Japan
- Research Site
-
Kurume, Fukuoka, Japan
- Research Site
-
-
Gifu
-
Hashima-gun, Gifu, Japan
- Research Site
-
-
Hiroshima
-
Fukuyama, Hiroshima, Japan
- Research Site
-
-
Hokkaido
-
Asahikawa, Hokkaido, Japan
- Research Site
-
Sapporo, Hokkaido, Japan
- Research Site
-
-
Hyogo
-
Kobe, Hyogo, Japan
- Research Site
-
-
Okayama
-
Kurashiki, Okayama, Japan
- Research Site
-
-
Osaka
-
Suita, Osaka, Japan
- Research Site
-
-
Saitama
-
Tokorozawa, Saitama, Japan
- Research Site
-
-
Tokyo
-
Shinjuku-ku, Tokyo, Japan
- Research Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Female or male aged ≥ 18 and ≤ 65 years
- Diagnosis of Crohn's Disease
Exclusion Criteria:
- Having ileostomy or pouch and/or colostomy
- Having previous gastric surgery
- Having a known or suspected systemic infection
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Placebo komparator: 3
Placebo
|
D9421-C matching placebo was given once daily for 8 weeks.
|
Aktiv komparator: 1
D9421-C 9 mg
|
D9421-C 9 mg was given once daily for 8 weeks.
|
Aktiv komparator: 2
D9421-C 15 mg
|
D9421-C 15 mg was given once daily for 8 weeks.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants Who Had Remission of Crohn's Disease After 8-week Treatment
Tidsramme: Baseline to 8 weeks
|
Remission is defined by a Crohn's Disease Activity Index (CDAI) score of ≤ 150.
That is, if a participant had 150 or less of CDAI score after 8-week treatment, the participant had the remission of Crohn's disease.
The number of participants who had remission of Crohn's disease after 8-week treatment was the primary measure of this study.
|
Baseline to 8 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants Who Had Remission of Crohn's Disease After 2-week Treatment
Tidsramme: Baseline to 2 weeks
|
The number of participants who had remission of Crohn's disease (i.e., CDAI score ≤ 150) after 2-week treatment was one of the secondary measures of this study.
|
Baseline to 2 weeks
|
Number of Participants Who Had Remission of Crohn's Disease After 4-week Treatment
Tidsramme: Baseline to 4 weeks
|
The number of participants who had remission of Crohn's disease (i.e., CDAI score ≤ 150) after 2-week treatment was one of the secondary measures of this study.
|
Baseline to 4 weeks
|
Cumulative Percentage of Participants Who Achieved Remission up to 8 Weeks by Kaplan-Meier Method
Tidsramme: At 8 weeks
|
Time from randomisation to the remission of Crohn's disease defined as CDAI score 150 was analysed by Kaplan-Miere method.
From this method, the cumulative percentage of participants who obtained up to 8 weeks were obtained.
|
At 8 weeks
|
Change in CDAI Score From Baseline to 8 Weeks
Tidsramme: Baseline to 8 weeks
|
CDAI score is an index showing the condition of Crohn's disease and has no unit.
The minimum is 0 and the maximum is not defined.
Higher score shows worse condition and a decrease in score means improvement.
In this study, participants who had 200 or higher of CDAI score were enrolled.
The change from baseline to 8 weeks in CDAI score was measured.
|
Baseline to 8 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: Masataka Date, MD, PhD, AstraZeneca
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. oktober 2006
Primær færdiggørelse (Faktiske)
1. marts 2008
Studieafslutning (Faktiske)
1. marts 2008
Datoer for studieregistrering
Først indsendt
13. december 2007
Først indsendt, der opfyldte QC-kriterier
13. december 2007
Først opslået (Skøn)
14. december 2007
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
12. juli 2012
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
2. juli 2012
Sidst verificeret
1. juli 2012
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- D9421C00002
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Crohns sygdom
-
Asan Medical CenterRekrutteringCrohns sygdom | Terapeutisk lægemiddelovervågning | Infliximab | Perianal fistel på grund af Crohns sygdom | Magnetic Resonance Novel Index for Fistel Imaging i Crohn's Disease ScoreKorea, Republikken
Kliniske forsøg med D9421-C, 9mg
-
AstraZenecaAfsluttet
-
University of AarhusUkendtMuskuloskeletal sygdom | Immunsystem sygdomDanmark
-
Ge JunboAfsluttetAkut ST-segment Elevation MyokardieinfarktKina
-
Herlev and Gentofte HospitalIkke rekrutterer endnuAllergisk kontaktdermatitis
-
PfizerAfsluttetHepatitis C virusForenede Stater
-
Hangzhou Grand Biologic Pharmaceutical, Inc.Peking Union Medical College HospitalUkendt
-
R-BioAfsluttetKnæ slidgigt | Degenerativ arthritisKorea, Republikken
-
PfizerAfsluttet
-
GTxAfsluttetMetastatisk brystkræftForenede Stater
-
Scandinavian Critical Care Trials GroupAarhus University Hospital; Rigshospitalet, Denmark; University of Copenhagen og andre samarbejdspartnereAfsluttet